Oxygenta Pharmaceutical Ltd

Oxygenta Pharmaceutical Ltd has announced the closure of its trading window for all designated persons, their immediate relatives, and connected persons. This closure is effective from July 1, 2026, and will remain in effect until 48 hours after the declaration of the audited financial results for the quarter ending June 30, 2026 (Q2 FY27). The company will schedule a Board Meeting to consider and approve these financial results. This measure is in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct to prevent insider trading.

Oxygenta Pharmaceutical Ltd's board approved the audited financial results for the quarter and year ended March 31, 2026. The board also approved the appointment of Mr. Amireddy Venkatesu Reddy as an Additional Director (Executive category) and Mr. Janardhana Reddy Yeddula as an Additional Director (Independent Category), both effective from May 23, 2026, subject to shareholder approval. Additionally, M/s. Suryachandra & Associates were appointed as Internal Auditors for FY 2026-27, and M/s. Aakanksha Dubey & Co. will serve as Scrutinizer for the e-voting process at the upcoming Annual General Meeting.

Oxygenta Pharmaceutical Ltd's board meeting on May 23, 2026, approved the appointment of Mr. Amireddy Venkatesu Reddy as an Additional Director (Executive category) for 3 years and Mr. Janardhana Reddy Yeddula as an Additional Director (Independent Category) for 5 years, both subject to shareholder approval. M/s. Suryachandra & Associates were appointed as Internal Auditors for FY 2026-27. The board also approved the audited financial results for the quarter and year ended March 31, 2026, and appointed M/s. Aakanksha Dubey & Co. as Scrutinizer for the e-voting process at the upcoming AGM.

Oxygenta Pharmaceutical Ltd's board meeting on May 23, 2026, approved the audited financial results for the quarter and year ended March 31, 2026. The board also appointed Mr. Amireddy Venkatesu Reddy as an Additional Director (Executive category) for 3 years and Mr. Janardhana Reddy Yeddula as an Additional Director (Independent Category) for 5 years, both subject to shareholder approval. Additionally, M/s. Suryachandra & Associates were appointed as Internal Auditors for FY 2026-27, and M/s. Aakanksha Dubey & Co. was appointed as Scrutinizer for the e-voting process at the upcoming Annual General Meeting.

Oxygenta Pharmaceutical Ltd has scheduled a Board of Directors meeting on May 23, 2026, to consider and approve the audited financial results for the quarter and year ended March 31, 2026, along with the audit report for the same period. The meeting will also address any other business with the chair's permission.

Oxygenta Pharmaceutical Limited (Scrip Code: 524636) has announced the closure of its trading window for dealing in the securities of the company. The closure will be in effect from 01.04.2026 till 48 hours after the declaration of audited Financial Results for the quarter and year ending 31.03.2026. This decision is in accordance with the Company’s Code of Conduct for Prevention of Insider Trading adopted under SEBI (Prohibition of Insider Trading) Regulations, 2015. The closure applies to all designated persons, their immediate relatives, and all connected persons covered under the Company’s Code of Conduct. The Board Meeting is scheduled to consider and approve the audited Financial Results for the quarter and year ending 31.03.2026. An intimation regarding the notice of the Board Meeting will be sent separately to the Stock Exchange.

Oxygenta Pharmaceutical Ltd., a subsidiary of Virupaksha Organics Limited, has announced the annulment of a disputed demand of Rs. 41,31,351 (Rupees Forty-One Lakhs Thirty-One Thousand Three Hundred and Fifty-One Only) raised by the Office of the Appellate Joint Commissioner of State Tax, Punjagutta Division. The demand was raised for the tax periods from 01-04-2017 to 31-03-2018 (2017-18) on account of ITC to be recovered on non-business transactions & exempt supplies. The company filed an appeal (No.AD3602240136692) on 24.02.2024, which was successful. The order was received on 19.02.2026, and there will be no impact on the company's financial, operational, or other activities.

Virupaksha Organics Ltd, a promoter of Oxygenta Pharmaceutical Ltd, has purchased 2,23,632 equity shares of the company on 13-02-2026. This acquisition represents 0.60% of the total voting rights of the company. The shares were purchased on the open/on market.

Virupaksha Organics Limited, a promoter of Oxygenta Pharmaceutical Limited, has purchased 2,23,632 equity shares of the company on 13-02-2026. This acquisition represents 0.60% of the total voting rights and equity share capital of Oxygenta Pharmaceutical Limited.

Oxygenta Pharmaceutical Ltd. has approved the unaudited financial results for the quarter and nine months ended 31st December 2025. The company's income from operations stands at Rs. 3,393.09 lakhs for Q3 and Rs. 14,2461 lakhs for the nine months period. The total expenses for the same periods are Rs. 6,348.07 lakhs and Rs. 61,0921 lakhs respectively. The profit from operations before other income and exceptional items for Q3 is Rs. 2,094.69 lakhs and Rs. 1,055.22 lakhs for the nine months period. The company has also re-constituted its Internal Complaints Committee under The Sexual Harassment of Women at Workplace (Prevention, Prohibition, and Redressal) Act, 2013.